Related Experiment Videos
Breast cancer response to hormone replacement therapy withdrawal
Lancet (London, England)
|June 3, 1995
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2022
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2017
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Annals of oncology : official journal of the European Society for Medical Oncology·2015
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
Annals of oncology : official journal of the European Society for Medical Oncology·2013
Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum.
Annals of the Royal College of Surgeons of England·2012
Risk of transmission of amyloid β pathology via transfused blood products.
Lancet (London, England)·2026